1. Pink Sheet

Sharpless Wonders Why Cancer Success Doesn't Translate To Other Diseases

 
• By Derrick Gingery

Acting US FDA commissioner also said he wants to be nominated to the permanent position.

FDA acting Commissioner Ned Sharpless at Reagan-Udall Foundation for FDA. (1)
Acting FDA Commissioner Norman Sharpless wants the success in cancer drug development disseminated to other disease areas. • Source: File photo

Acting US Food and Drug Administration Commissioner Norman Sharpless wants the oncology community to share the secret of its regulatory success.

During an event on cancer care and policy, Sharpless wondered whether additional tools are necessary to translate the level of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Could Study Questioning GLP-1 Cost Savings Impact CMMI Demo Chances?

 
• By Cathy Kelly

The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.

Why Chiesi’s Raxone Faced A Decade-Long Wait For English Funding

 
• By Eliza Slawther

Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

 
• By Neena Brizmohun

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.